A review of pulmonary arterial hypertension: Role of ambrisentan

Vascular Health and Risk Management

Volumn 3, Issue 1, 2007, Pages 11-22

  Barst, Robyn J ^a  

^a New York Presbyterian Pulmonary Hypertension Center ^*  (United States)

Author keywords

Borg dyspnea index; Endothelin receptor antagonist; Endothelin 1; Pulmonary arterial hypertension; Time to clinical worsening

Indexed keywords

ALANINE AMINOTRANSFERASE; AMBRISENTAN; AMINOREX; ANOREXIGENIC AGENT; ASPARTATE AMINOTRANSFERASE; BOSENTAN; CONTRACEPTIVE AGENT; CYCLOSPORIN A; CYTOCHROME P450; DEXFENFLURAMINE; ENDOTHELIN 1; ENDOTHELIN A RECEPTOR; ENDOTHELIN B RECEPTOR; FENFLURAMINE; GLIBENCLAMIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ILOPROST; LU 208075; NITRIC OXIDE; PLACEBO; PROSTACYCLIN; PROSTACYCLIN DERIVATIVE; PROSTANOID; SILDENAFIL; SITAXSENTAN; TADALAFIL; THROMBOXANE A2; UNCLASSIFIED DRUG; UNINDEXED DRUG; UNIPROST; VASOACTIVE AGENT; WARFARIN;

BLEEDING; BLOOD PRESSURE MEASUREMENT; CARDIOVASCULAR RISK; CATHETER INFECTION; CAUSE OF DEATH; CLINICAL FEATURE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONGENITAL HEART DISEASE; CONTINUOUS INFUSION; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG ABSORPTION; DRUG ANTAGONISM; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; DRUG SAFETY; DRUG STRUCTURE; DRUG TISSUE LEVEL; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; ERECTILE DYSFUNCTION; EXERCISE TOLERANCE; FLUSHING; FOOD; FOOD DRUG INTERACTION; HEART FAILURE; HEMOGLOBIN DETERMINATION; HISTOPATHOLOGY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INJECTION SITE PAIN; LIVER FUNCTION TEST; LIVER TOXICITY; MONOTHERAPY; MORTALITY; NAUSEA; NONHUMAN; NOSE CONGESTION; PATHOPHYSIOLOGY; PERIPHERAL EDEMA; PORTAL HYPERTENSION; PROGNOSIS; PROTEIN DETERMINATION; PROTEIN FUNCTION; PULMONARY HYPERTENSION; QUALITY OF LIFE; RECEPTOR AFFINITY; RECEPTOR BLOCKING; REVIEW; RISK ASSESSMENT; RISK FACTOR; SIDE EFFECT; SINGLE DRUG DOSE; UPPER RESPIRATORY TRACT INFECTION; VASODILATATION;

ENDOTHELIN-1; EXERCISE; HUMANS; HYPERTENSION, PULMONARY; MUSCLE, SMOOTH, VASCULAR; PHENYLPROPIONATES; PULMONARY WEDGE PRESSURE; PYRIDAZINES; RECEPTORS, ENDOTHELIN; TREATMENT OUTCOME; VASCULAR RESISTANCE;

EID: 34249854139     PISSN: 11766344     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (72)

1. Abenhaim L, Moride Y, Brenot F, et al. 1996. Appetite-suppressant drugs and the risk of primary pulmonary hypertension. International Primary Pulmonary Hypertension Study Group. N Engl J Med, 335:609-16.
2. Ahn HS, Foster M, Cable M, et al. 1991. Ca/CaM-stimulated and cGMP-specific phosphodiesterases in vascular and non-vascular tissues. Adv Exp Med Biol, 308:191-7.
3. Badesch DB, Abman SH, Ahearn GS, et al. 2004a. Medical therapy for pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest, 126:35S-62S.
4. Barst RJ, Langleben D, Badesch D, et al. 2006. Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan. J Am Coll Cardiol, 47:2049-56.
5. Barst RJ, Langleben D, Frost A, et al. 2004a. Sitaxsentan therapy for pulmonary arterial hypertension. Am J Respir Crit Care Med, 169:441-7.
6. Badesch DB, McLaughlin VV, Delcroix M, et al. 2004b. Prostanoid therapy for pulmonary arterial hypertension. J Am Coll Cardiol, 43:56S-61S.
7. Barst RJ, McGoon M, Torbicki A, et al. 2004b. Diagnosis and differential assessment of pulmonary arterial hypertension. J Am Coll Cardiol, 43:40S-7S.
8. Barst RJ, Maislin G, Fishman AP. 1999. Vasodilator therapy for primary pulmonary hypertension in children. Circulation, 99:1197-208.
9. Barst RJ, Rubin LJ, Long WA, et al. 1996. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for prunary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group. N Engl J Med, 334:296-302.
10. Barst RJ, Rubin LJ, McGoon MD, et al. 1994. Survival in primary pulmonary hypertension with long-term continuous intravenous prostacyclin. Ann Intern Med, 121:409-15.
11. Baumhakel M, Cremers B, Bohm M. 2005. Current Therapy of Pulmonary Hypertension. Herz, 30:303-10.
12. Beavo, JA, Reifsnyder DH. 1990. Primary sequence of cyclic nucleotide phosphodiesterase isozymes and the design of selective inhibitors. Trends Pharmacol Sci, 11:150-5.
13. Billman GE. 2002. Ambrisentan (Myogen). Curr Opin Investig Drugs, 3:1483-6.
14. Botney MD. 1999. Role of hemodynamics in pulmonary vascular remodeling: implications for primary pulmonary hypertension. Am J Respir Crit Care Med, 159:361-4.
15. Braner DA, Fineman JR, Chang R, et al. 1993, M&B 22948, a cGMP phosphodiesterase inhibitor, is a pulmonary vasodilator in lambs. Am J Physiol, 264:H252-8.
16. Cacoub P, Dorent R, Maistre G, et al. 1993. Endothelin-1 in primary pulmonary hypertension and the Eisenmenger syndrome. Am J Cardiol, 71:448-50.
17. Cacoub P, Dorent R, Nataf P, et al. 1997. Endothelin-1 in the lungs of patients with pulmonary hypertension. Cardiovasc Res, 33:196-200.
18. Channick RN, Simonneau G, Sitbon O, et al. 2001. Effect of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet, Oct 6; 358(9288):1119-23.
19. Christman BW, McPherson CD, Newman JH, et al. 1992. An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. N Engl J Med, 327:70-5.
20. D'Alonzo GE, Barst RJ, Ayres SM, et al. 1991. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med, 115:343-9.
21. Dingemanse J, van Giersbergen PL. 2004. Clinical pharmacology of bosentan, a dual endothelin receptor antagonist. Clin Pharmacokinet, 43:1089-115.
22. Dupuis J. 2001. Endothelin-receptor antagonists in pulmonary hypertension. Lancet, 358:1113-4.
23. Dufton C, Gerber MJ, Yin O, et al. 2006. No clinically relevant pharmacokinetic interaction between ambrisentan and sildenafil. Chest, 130:254S.
24. Edwards WD, Edwards JE. 1977. Clinical primary pulmonary hypertension: three pathologic types. Circulation, 56:884-8.
25. Farber HW, Loscalzo J. 2004. Pulmonary arterial hypertension. N Engl J Med, 351:1655-65.
26. Fattinger K, Funk C, Pantze M, et al. 2001. The endothelin antagonist bosentan inhibits the canalicular bile salt export pump: a potential mechanism for hepatic adverse reactions. Clin Pharmacol Ther, 69:223-31.
27. Fouassier L, Kinnman N, Lefevre G, et al. 2002. Contribution of mrp2 in alterations of canalicular bile formation by the endothelin antagonist bosentan. J Hepatol, 37:184-91.
28. Galie N, Badesch D, Oudiz R, et al. 2005a. Ambrisentan therapy for pulmonary arterial hypertension. J Am Coll Cardiol, 46:529-35.
29. Galie N, Ghofrani HA, Torbicki A, et al. 2005b. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med, 353:2148-57.
30. Galie N, Keogh AM, Frost A, et al. 2005c. Ambrisentan long-term safety and efficacy in pulmonary arterial hypertension-one year follow up. Proc Am Thorac Soc, 2:A299.
31. Galie N, Manes A, Branzi A. 2004. The endothelin system in pulmonary arterial hypertension. Cardiovase Res, 61:227-37.
32. Gerber MJ, Dufton C, Pentikis H, et al. 2006. Ambrisentan has no clinically relevant effect on the pharmacokinetics or pharmacodynamics of warfarin. Chest, 130:256S.
33. Gerber JG, Voelkel N, Nies AS, et al. 1980. Moderation of hypoxic vasoconstriction by infused arachidonic acid: role of PGI2. J Appl Physiol, 49:107-12.
34. Giaid A, Saleh D. 1995. Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension. N Engl J Med, 333:214-21.
35. Giaid A, Yanagisawa M, Langleben D, et al. 1993. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med, 328:1732-9.
36. B receptor selectivity of endothelin-1 receptor antagonists in human myocardial membranes. J Am Coll Cardiol, 47:307A.
37. Hassoun PM, Thappa V, Landman MJ, et al. 1992. Endothelin 1: mitogenic activity on pulmonary artery smooth muscle cells and release from hypoxic endothelial cells. Proc Soc Exp Biol Med, 199:165-70.
38. Hatano S, Strasser T, eds. 1975. Primary Pulmonary Hypertension. Report on a WHO Meeting. Geneva: World Health Organization. p. 7-45.
39. Higenbottam TW, Laude EA. 1998. Endothelial dysfunction providing the basis for the treatment of pulmonary hypertension: Giles F. Filley lecture. Chest, 114:72S-9S.
40. Hirata Y, Emori T, Eguchi S, et al. 1993. Endothelin receptor subtype B mediates synthesis of nitric oxide by cultured bovine endothelial cells. J Clin Invest, 91:1367-73.
41. Hoeper MM. 2005. Drug treatment of pulmonary arterial hypertension: current and fature agents. Drugs, 65:1337-54.
42. Humbert M, Nunes H, Sitbon O, et al. 2001. Risk factors for pulmonary arterial hypertension. Clin Chest Med, 22:459-75.
43. Humbert M, Sitbon O, Simonneau G. 2004. Treatment of pulmonary arterial hypertension. N Engl J Med, 351:1425-36.
44. Kenyon KW, Nappi JM. 2003. Bosentan for the treatment of pulmonary arterial hypertension. Ann Pharmacother, 37:1055-62.
45. McGoon M, Frost A, Oudiz R, et al. 2006. Ambrisentan rescue therapy in patients with pulmonary arterial hypertension who discontinued bosentan or sitaxsentan due to liver function abnormalities. Chest, 130:254S.
46. McLaughlin VV, Genthner DE, Panella MM, et al. 1998. Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension. N Engl J Med, 338:273-7.
47. McLaughlin VV, Presberg KW, Doyle RL, et al. 2004. Prognosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest, 126:78S-92S.
48. Nootens M, Kaufmann E, Rector T, et al. 1995. Neurohormonal activation in patients with right ventricular failure from pulmonary hypertension: relation to hemodynamic variables and endothelin levels. J Am Coll Cardiol, 26:1581-5.
49. Ohlstein EH, Arleth A, Bryan H, et al. 1992. The selective endothelin ETA receptor antagonist BQ123 antagonizes endothelin-1-mediated mitogenesis. Eur J Pharmacol, 225:347-50.
50. Olschewski H, Galie N, Ghofrani HA, et al. 2006. Ambrisentan improves exercise capacity and time to clinical worsening in patients with pulmonary arterial hypertension: Results of the ARIES-2 study. Proc Am Thorac Soc, 3:A728.
51. Opravil M, Pechere M, Speich R, et al. 1997. HIV-associated primary pulmonary hypertension. A case control study. Swiss HIV Cohort Study. Am J Respir Crit Care Med, 155:990-5.
52. Oudiz R, Torres F, Frost A, et al. 2006. ARIES-1: A placebo-controlled efficacy and safety study of ambrisentan in patients with pulmonary arterial hypertension. Chest, 130:121S.
53. Pietra GG, Edwards WD, Kay JM, et al. 1989. Histopathology of primary pulmonary hypertension. A qualitative and quantitative study of pulmonary blood vessels from 58 patients in the National Heart, Lung, and Blood Institute, Primary Pulmonary Hypertension Registry. Circulation, 80:1198-206.
54. Pollock DM, Keith TL, Highsmith RF. 1995. Endothelin receptors and calcium signaling. Faseb J, 9:1196-204.
55. Rich S, Dantzker DR, Ayres SM, et al. 1987. Primary pulmonary hypertension. A national Prospective study. Ann Intern Med, 107:216-23.
56. Rich S, Rubin L, Walker AM, et al. 2000. Anorexigens and pulmonary hypertension in the United States: results from the surveillance of North American pulmonary hypertension. Chest, 117:870-4.
57. Rich S. 2001. Pulmonary Hypertension. In Braunwald E, Zipes DP, Libby P (eds). Heart Disease: A Textbook of Cardiovascular Medicine. Philadelphia, PA.: WB Saunders. p. 1912-29.
58. Rubens C, Ewert R, Halank M, et al. 2001. Big endothelin-1 and endothelin-1 plasma levels are correlated with the severity of primary pulmonary hypertension. Chest, 120:1562-9.
59. Rubin LJ, Badesch DB, Barst RJ, et al. 2002. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med, 346:896-903.
60. Rubin LJ. 2006. Pulmonary arterial hypertension. Proc Am Thorac Soc, 3:111-5.
61. Rubin LJ, Badesch DB. 2005a. Evaluation and management of the patient with pulmonary arterial hypertension. Ann Intern Med, 143:282-92.
62. Rubin LJ, Dufton C, Gerber MJ. 2005b. Ambrisentan for pulmonary arterial hypertension. Future Cardiol, 1:1-8.
63. Shapiro SM, Oudiz RJ, Cao T, et al. 1997. Primary pulmonary hypertension: improved long-term effects and survival with continuous intravenous epoprostenol infusion. J Am Coll Cardiol, 30:343-9.
64. Simonneau G, Fartoukh M, Sitbon O, et al. 1998. Primary pulmonary hypertension associated with the use of fenfluramine derivatives. Chest, 114:195S-9S.
65. Simonneau G, Galie N, Rubin LJ, et al. 2004. Clinical classification of pulmonary hypertension. J Am Coll Cardiol, 43:5S-12S.
66. Stelzner TJ, O'Brien RF, Yanagisawa M, et al. 1992. Increased lung endothelin-1 production in rats with idiopathic pulmonary hypertension. Am J Physiol, 262:L614-20.
67. Stupi AM, Steen VD, Owens GR, et al. 1986. Pulmonary hypertension in the CREST syndrome variant of systemic sclerosis. Arthritis Rheum, 29:515-24.
68. Tuder RM, Cool CD, Geraci MW, et al. 1999. Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension. Am J Respir Crit Care Med, 159:1925-32.
69. UNAIDS. 2006. 2006 Report onthe global AIDS epidemic. 10th ed. Geneva: Joint United Nations Programme on HIV/AIDS (UNAIDS). p. 8-50.
70. Vane JR, Anggard EE, Botting RM. 1990. Regulatory functions of the vascular endothelium. N Engl J Med, 323:27-36.
71. Vlahakes GJ, Turley K, Hoffman JI. 1981. The pathophysiology of failure in acute right ventricular hypertension: hemodynamic and biochemical correlations. Circulation, 63:87-95.
72. Weimann J, Ullrich R, Hromi J, et al. 2000. Sildenafil is a pulmonary vasodilator in awake lambs with acute pulmonary hypertension. Anesthesiology, 92:1702-12.